TUMOR TREATING FIELDS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The tumor treating fields market size was valued at US$ 333.8 million in 2023 and is projected to reach US$ 915.3 million by 2030, growing at a CAGR of 15.5% from 2023 to 2030.

Tumor treating fields (TT Fields) are alternating electric fields applied to the region of a tumor to disrupt cancer cell division. TT Fields are used as a cancer treatment alongside chemotherapy, radiation therapy, immunotherapy, and surgery. The key advantages of TT Fields include being non-invasive, ease of use, minimal side effects, and ability to target dividing cancer cells specifically. The increasing prevalence of cancer globally is a major driver spurring the growth of the tumor treating fields market.

The tumor treating fields market is segmented by product type, indication, end user, and region. By product type, the market is segmented into transducer arrays, tumor treating field generators, and others. The transducer arrays segment accounts for the largest share of the market owing to the recurrent use of disposable transducer arrays in TT Fields therapy.

Tumor Treating Fields Market Regional Insights:

• North America is expected to be the largest market for tumor treating field market during the forecast period, accounting for over 42.9% of the market share in 2023. The growth of the market in North America is attributed to the high incidence of cancer, presence of major market players, and high awareness regarding TT Fields therapy.
• The Europe market is expected to be the second-largest market for tumor treating fields market, accounting for over 27.0% of the market share in 2022. The growth of the market in Europe is attributed to the rising incidence of brain tumors, favorable reimbursement policies, and increase in cancer research funding.
• The Asia Pacific market is expected to be the fastest-growing market for tumor treating fields market, with a CAGR of over 23.0% during the forecast period. The growth of the market in Asia Pacific is attributed to the large target population, improving healthcare infrastructure, and increasing healthcare expenditure.

Figure 1. Global Tumor Treating Fields Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Tumor Treating Fields Market – Analyst’s Views:

The tumor treating fields market is expected to grow steadily over the forecast period driven by increasing prevalence of cancer globally. Rising incidence of brain cancer along with regulatory approvals for new indications will further bolster adoption of tumor treating fields therapy. However, high costs associated with tumor treating fields devices and therapy may limit the market growth. The North American region is expected to dominate the tumor treating fields market owing to high awareness levels coupled with sizeable research and development investments from key market players based in the U.S. Asia Pacific is anticipated to witness the fastest growth on account of large patient population and improving access to advanced cancer treatments across developing nations. New product launches catering to different cancer types and improved device designs for enhanced patient comfort represent key areas of opportunity in the tumor treating fields market.

Tumor Treating Fields Market Drivers:

• Rising prevalence of cancer globally: The rising prevalence of cancer globally is a major factor driving growth in the tumor treating fields market. For instance, according to the World Health Organization, in July 2023, globally there were around 685,000 number of death due to breast cancer and 2.3 million women were diagnosed with breast cancer globally in 2020. With cancer rates on the rise, the demand for innovative new treatments like TTFields will surge. TTFields therapy has seen growing adoption for solid tumor indications like glioblastoma, pancreatic cancer, mesothelioma, and others. The therapy’s advantages as a non-invasive option with minimal side effects make it an appealing treatment choice as cancer rates rise worldwide.
• Increasing research and investments in cancer therapies: Extensive research is underway globally to develop improved cancer treatments and enhance patient outcomes. Governments, private institutions and organizations are increasingly investing in R&D in this area. The introduction of newer technologies like TTFields has sparked particular interest. Investments by organizations like the National Cancer Institute in the U.S. allow for more studies on TTFields therapy for additional cancer types. Research also focuses on evaluating combination approaches with radiation, immunotherapy and chemotherapy. These developments are expected to drive adoption of TTFields treatment.

Tumor Treating Fields Market Opportunities:

• High potential in emerging and developing regions: TTFields therapy has high penetration potential in emerging and developing regions globally. These markets are witnessing increasing cancer prevalence combined with improving healthcare infrastructure and spending. However, TTFields therapy availability remains limited currently. Targeting these underserved markets through strategic partnerships and expanding production capacity presents an opportunity. Cultivating relationships with regional governments and providers can ease access. Considering the large target patient populations and rising healthcare spending, improving availability in emerging regions can significantly propel tumor treating fields market growth.
• Developing next-gen and patient-friendly TTFields delivery systems: Developing next-generation and more patient-friendly TTFields delivery systems presents a key growth opportunity. Current TTFields devices face limitations like bulky equipment and skin irritation that impact patient compliance. Enhancements like smaller and more portable device designs, improved transducer arrays, and user-friendly software can help overcome these challenges.

Tumor Treating Fields Market Trends:

• Increasing investments and focus on enhancing R&D productivity: TTFields therapy developers are increasing investments aimed at boosting research and development (R&D) productivity. Investments aim to enhance areas like study design, patient targeting, data analytics, and clinical operations. Key market players are also entering partnerships with contract research organizations focused on enhancing trial execution. These trends are increasing the efficiency of TTFields clinical evaluations. Subsequently, therapy developers are able to evaluate more cancer indications and treatment combinations in shorter timeframes. More streamlined R&D is helping accelerate regulatory submissions and expand TTFields therapy applications.
• Emergence of specialty TTFields clinics and centers: TTFields-focused specialty clinics and treatment centers are emerging globally. These dedicated centers are staffed by expert, multidisciplinary teams specialized in TTFields therapy. They guide patients through the evaluation, fitting, training and ongoing compliance needed for optimal outcomes with TTFields. Centers leverage a patient-centric approach and data integration for precision care. Leading academic hospitals are also establishing dedicated oncology departments focused on TTFields therapy. These specialty centers allow for efficient patient pool creation for clinical studies as well. Increased training for physicians at these centers is also driving referral volumes and adoption.

Tumor Treating Fields Market Restraints:

• Limited awareness about TTFields therapy among patients and physicians: Limited awareness about TTFields therapy among patients and physicians has constrained adoption so far. TTFields is a relatively new treatment modality approved in the last decade. Most patients remain unaware that the non-invasive electric field treatment option exists alongside traditional therapies like chemotherapy. Physician awareness is also low beyond oncologists specializing in glioblastoma or other approved indications. Lack of knowledge leads to hesitancy among patients. Overcoming this requires significant investments in education programs and advocacy. Increased awareness initiatives focused on patients and physicians can help drive understanding and adoption of this innovative therapy.
• High costs associated with device and therapy: The high costs associated with devices and therapy are significantly restraining the growth of the tumor treating fields market. Tumor treating field therapy requires using an electrical field tuning unit and transducer arrays that need to be placed on the patient's shaved scalp. These devices and the therapy sessions are highly expensive for patients. Additionally, the therapy sessions have to be administered for a minimum of 18 hours a day, making it an expensive long-term treatment compared to chemotherapy or radiation. For instance, according to an article published in the National Library of Medicine, in May 2020, the average cost of tumor treating field’s therapy in the U.S. is around US$ 12,676 per month or per session.
• Need for frequent monitoring and clinician engagement: TTFields therapy requires ongoing patient monitoring and engagement from clinicians. The transducer arrays must be correctly placed and replaced 2-3 times per week. Clinicians need to regularly check therapy compliance data and monitor for side effects like skin irritation. However, heavy patient loads limit physicians’ capacity to provide this level of oversight. The patient burden of continuous monitoring can impact compliance as well. Adequate support staffing and leveraging digital tools for remote monitoring can help address this challenge. But scaling these support channels requires time and investment, restraining adoption currently.

Recent Developments:

New product launches and approval:

• In November 2022, Novocure GmbH, a Germany-based medical device company, announced that Health Canada has approved Optune for the treatment of newly diagnosed and recurrent glioblastoma (GBM).
• In November 2020, Novocure GmbH announced that U.S. FDA had approved the NovoTTF-100L System (known as Optune Lua in the U.S.) as a treatment for malignant pleural mesothelioma (MPM).
• In June 2020, Novocure GmbH announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist.

Figure 2. Global Tumor Treating Fields Market Share (%), by Product Type, 2023

To learn more about this report, request sample copy

Top companies in Tumor Treating Fields Market:

• Novocure GmbH
• Zai Lab

Definition: The tumor treating fields disrupt solid tumor cancer cell division through low-intensity, intermediate frequency electric fields. The non-invasive fields are delivered through transducer arrays placed on the skin near the tumor site. TTFields therapy is used alongside other standard cancer treatments to enhance outcomes in patients. Key applications currently include treating glioblastoma, mesothelioma, pancreatic cancer and other solid tumor indications.

Few Other Promising Reports in Medical Devices Industry

Cancer Therapy Market

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market

Cancer Immunotherapy Market

Brain Cancer Therapeutics Market